
Victor N Sakran
Examiner (ID: 15805)
| Most Active Art Unit | 3507 |
| Art Unit(s) | 3507, 3505, 3677, 3626, 2899 |
| Total Applications | 3429 |
| Issued Applications | 3196 |
| Pending Applications | 92 |
| Abandoned Applications | 141 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17719048
[patent_doc_number] => 20220211767
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => ENHANCEMENT OF FIBROBLAST THERAPEUTIC ACTIVITY BY T CELL MODULATION
[patent_app_type] => utility
[patent_app_number] => 17/594730
[patent_app_country] => US
[patent_app_date] => 2020-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9115
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594730
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/594730 | ENHANCEMENT OF FIBROBLAST THERAPEUTIC ACTIVITY BY T CELL MODULATION | Apr 26, 2020 | Pending |
Array
(
[id] => 16397305
[patent_doc_number] => 20200338163
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => COMPOSITIONS AND METHODS FOR CARDIAC TISSUE REPAIR
[patent_app_type] => utility
[patent_app_number] => 16/858154
[patent_app_country] => US
[patent_app_date] => 2020-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16363
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16858154
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/858154 | Methods for cardiac tissue repair with compositions comprising CTGF | Apr 23, 2020 | Issued |
Array
(
[id] => 16375113
[patent_doc_number] => 20200323955
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-15
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION
[patent_app_type] => utility
[patent_app_number] => 16/851287
[patent_app_country] => US
[patent_app_date] => 2020-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13024
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16851287
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/851287 | Methods for treating pulmonary hypertension with a ligand binding domain of a TGF-beta type II receptor | Apr 16, 2020 | Issued |
Array
(
[id] => 16362445
[patent_doc_number] => 20200319196
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-08
[patent_title] => USE OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS IN THE MANAGEMENT OF PATIENTS WITH CARDIOVASCULAR DISEASE
[patent_app_type] => utility
[patent_app_number] => 16/838711
[patent_app_country] => US
[patent_app_date] => 2020-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18915
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16838711
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/838711 | USE OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS IN THE MANAGEMENT OF PATIENTS WITH CARDIOVASCULAR DISEASE | Apr 1, 2020 | Abandoned |
Array
(
[id] => 17281694
[patent_doc_number] => 11198714
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-14
[patent_title] => Synthetic truncated norrin protein
[patent_app_type] => utility
[patent_app_number] => 16/829283
[patent_app_country] => US
[patent_app_date] => 2020-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 22
[patent_no_of_words] => 11930
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16829283
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/829283 | Synthetic truncated norrin protein | Mar 24, 2020 | Issued |
Array
(
[id] => 17713510
[patent_doc_number] => 11377493
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-05
[patent_title] => Method for treating cancer with c-kit antibodies
[patent_app_type] => utility
[patent_app_number] => 16/818149
[patent_app_country] => US
[patent_app_date] => 2020-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 53
[patent_figures_cnt] => 53
[patent_no_of_words] => 29069
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 186
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16818149
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/818149 | Method for treating cancer with c-kit antibodies | Mar 12, 2020 | Issued |
Array
(
[id] => 19150164
[patent_doc_number] => 11975054
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-07
[patent_title] => Nucleic acid molecules encoding clostridium histolyticum collagenase I and methods of producing the same
[patent_app_type] => utility
[patent_app_number] => 16/816097
[patent_app_country] => US
[patent_app_date] => 2020-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 16584
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16816097
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/816097 | Nucleic acid molecules encoding clostridium histolyticum collagenase I and methods of producing the same | Mar 10, 2020 | Issued |
Array
(
[id] => 16267352
[patent_doc_number] => 20200268839
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-27
[patent_title] => COMPOSITION FOR TREATING PULMONARY FIBROSIS AND EMPHYSEMA AND THERAPEUTIC METHOD USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/798953
[patent_app_country] => US
[patent_app_date] => 2020-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4963
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16798953
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/798953 | COMPOSITION FOR TREATING PULMONARY FIBROSIS AND EMPHYSEMA AND THERAPEUTIC METHOD USING THE SAME | Feb 23, 2020 | Abandoned |
Array
(
[id] => 17378143
[patent_doc_number] => 11236140
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-02-01
[patent_title] => Interleukin 15 fusion protein for tumor targeting therapy
[patent_app_type] => utility
[patent_app_number] => 16/798269
[patent_app_country] => US
[patent_app_date] => 2020-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 15
[patent_no_of_words] => 5584
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16798269
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/798269 | Interleukin 15 fusion protein for tumor targeting therapy | Feb 20, 2020 | Issued |
Array
(
[id] => 16297819
[patent_doc_number] => 20200283542
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA
[patent_app_type] => utility
[patent_app_number] => 16/793643
[patent_app_country] => US
[patent_app_date] => 2020-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 88247
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16793643
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/793643 | ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA | Feb 17, 2020 | Abandoned |
Array
(
[id] => 16704365
[patent_doc_number] => 10954285
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-23
[patent_title] => Humanized anti-PACAP antibodies
[patent_app_type] => utility
[patent_app_number] => 16/787250
[patent_app_country] => US
[patent_app_date] => 2020-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 61
[patent_figures_cnt] => 157
[patent_no_of_words] => 105235
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 127
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787250
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/787250 | Humanized anti-PACAP antibodies | Feb 10, 2020 | Issued |
Array
(
[id] => 16743293
[patent_doc_number] => 10968268
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-06
[patent_title] => Humanized anti-PACAP antibodies
[patent_app_type] => utility
[patent_app_number] => 16/787313
[patent_app_country] => US
[patent_app_date] => 2020-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 61
[patent_figures_cnt] => 157
[patent_no_of_words] => 105251
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 127
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787313
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/787313 | Humanized anti-PACAP antibodies | Feb 10, 2020 | Issued |
Array
(
[id] => 16770896
[patent_doc_number] => 10981985
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-20
[patent_title] => Anti-PACAP antibodies
[patent_app_type] => utility
[patent_app_number] => 16/787294
[patent_app_country] => US
[patent_app_date] => 2020-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 96
[patent_no_of_words] => 56642
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 97
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787294
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/787294 | Anti-PACAP antibodies | Feb 10, 2020 | Issued |
Array
(
[id] => 15963129
[patent_doc_number] => 20200165316
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-28
[patent_title] => HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/787260
[patent_app_country] => US
[patent_app_date] => 2020-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 105230
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16787260
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/787260 | Humanized anti-PACAP antibodies | Feb 10, 2020 | Issued |
Array
(
[id] => 18102465
[patent_doc_number] => 11542341
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-03
[patent_title] => Kit for detecting coronary artery disease comprising an MAA protein adduct and reagents that bind to antibodies
[patent_app_type] => utility
[patent_app_number] => 16/782015
[patent_app_country] => US
[patent_app_date] => 2020-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 13
[patent_no_of_words] => 21093
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 89
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782015
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/782015 | Kit for detecting coronary artery disease comprising an MAA protein adduct and reagents that bind to antibodies | Feb 3, 2020 | Issued |
Array
(
[id] => 16238608
[patent_doc_number] => 20200255842
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => LONG-ACTING G-CSF FOR PREVENTING NEUTROPENIA OR REDUCING DURATION OF NEUTROPENIA
[patent_app_type] => utility
[patent_app_number] => 16/748057
[patent_app_country] => US
[patent_app_date] => 2020-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22288
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 229
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16748057
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/748057 | Long-acting G-CSF for preventing neutropenia or reducing duration of neutropenia | Jan 20, 2020 | Issued |
Array
(
[id] => 17458780
[patent_doc_number] => 20220072084
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => THERAPEUTIC NANOCONJUGATES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/423549
[patent_app_country] => US
[patent_app_date] => 2020-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18237
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17423549
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/423549 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | Jan 15, 2020 | Pending |
Array
(
[id] => 17611548
[patent_doc_number] => 20220153827
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => Anti-TNF Antibody Compositions and Methods for the Treatment of Juvenile Idiopathic Arthritis
[patent_app_type] => utility
[patent_app_number] => 17/423177
[patent_app_country] => US
[patent_app_date] => 2020-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69620
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17423177
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/423177 | Anti-TNF Antibody Compositions and Methods for the Treatment of Juvenile Idiopathic Arthritis | Jan 13, 2020 | Pending |
Array
(
[id] => 16435726
[patent_doc_number] => 20200353051
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => Chimeric Immunoreceptor Useful in Treating Human Cancers
[patent_app_type] => utility
[patent_app_number] => 16/723782
[patent_app_country] => US
[patent_app_date] => 2019-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12281
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16723782
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/723782 | Chimeric immunoreceptor useful in treating human cancers | Dec 19, 2019 | Issued |
Array
(
[id] => 16206565
[patent_doc_number] => 20200239555
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/714294
[patent_app_country] => US
[patent_app_date] => 2019-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33910
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16714294
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/714294 | Polynucleotides encoding anti-ApoC3 antibodies | Dec 12, 2019 | Issued |